Floatz logo

Azacitidine

Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1

National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 2BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BB
Rapamycin
Fred Hutchinson Cancer Center
Phase 2B
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2B
Fludarabine
Fred Hutchinson Cancer Center
Phase 2B

View all 20 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →
acute erythroid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →